1. PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of life
- Author
-
Rebecca Ford, Elke J. Seppanen, Camilla de Gier, Jacinta Francis, Tilda Orami, Karli J. Corscadden, William Pomat, Audrey Michael, Mition Yoannes, Lea Ann S. Kirkham, Caitlyn Granland, Peter Jacoby, Ruth B. Thornton, Tasmina Rahman, Deborah Lehmann, K. Martinovich, Anita H. J. van den Biggelaar, and Peter Richmond
- Subjects
030231 tropical medicine ,Population ,medicine.disease_cause ,Pneumococcal Infections ,Pneumococcal conjugate vaccine ,Haemophilus influenzae ,Pneumococcal Vaccines ,Papua New Guinea ,03 medical and health sciences ,0302 clinical medicine ,Nasopharynx ,otorhinolaryngologic diseases ,medicine ,Humans ,030212 general & internal medicine ,Child ,education ,education.field_of_study ,General Veterinary ,General Immunology and Microbiology ,biology ,business.industry ,Public Health, Environmental and Occupational Health ,Infant ,medicine.disease ,Vaccination ,Pneumonia ,Infectious Diseases ,Otitis ,Carriage ,Immunoglobulin G ,Carrier State ,Immunology ,biology.protein ,Molecular Medicine ,medicine.symptom ,Antibody ,business ,medicine.drug - Abstract
Background Nasopharyngeal colonisation with nontypeable Haemophilus influenzae (NTHi) is associated with development of infections including pneumonia and otitis media. The 10-valent pneumococcal conjugate vaccine (PCV10) uses NTHi Protein D (PD) as a carrier. Papua New Guinean children have exceptionally early and dense NTHi carriage, and high rates of NTHi-associated disease. Vaccination with PCV10 could potentially reduce NTHi carriage and disease in this population by inducing a NTHi PD immune response. Methods Serum and nasopharyngeal swabs were collected from 101 Papua New Guinean children at 1, 4, 9, 10, 23 and 24 months of age. Children received PCV10 (n = 55) or PCV13 (not containing NTHi PD) (n = 46) at 1, 2 and 3 months of age. NTHi carriage density was measured in swabs by qPCR. Serum PD-IgG levels were measured by bead-based immunoassay. Results Papua New Guinean children did naturally develop PD-IgG antibodies whose levels were increased at 4 months of age with PCV10 vaccination at 1–2-3 months. Despite this, most children were colonised with NTHi by 4 months of age (~95%) regardless of being vaccinated with PCV10 or PCV13, and PCV10 had no impact on NTHi carriage density. Conclusion Early vaccination of infants with PCV10 elicited a robust PD antibody response but this had no impact on NTHi carriage. Trial registration ClinicalTrials.gov CTN NCT01619462.
- Published
- 2021